Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform

Cowen & Co. analyst Phil Nadeau downgrades PhaseBio Pharmaceuticals (NASDAQ:PHAS) from Outperform to Market Perform.

byBenzinga Newsdesk

October 24, 2022

1 minute read

Cowen & Co. analyst Phil Nadeau downgrades PhaseBio Pharmaceuticals (NASDAQ:PHAS) from Outperform to Market Perform.

21 Stocks Moving in Monday’s Pre-Market Session

By Lisa Levin

Today, 11:01 PM

Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 41.5% to $1.91 in pre-market trading. Ipsen and Exicure signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids targeting rare neurodegenerative disorders.

AFRM

Analyst Ratings

Analyst Ratings For Take-Two Interactive

By Benzinga Insights

Today, 11:01 PM

Analysts have provided the following ratings for Take-Two Interactive (NASDAQ:TTWO) within the last quarter:

TTWO

Morgan Stanley Maintains Equal-Weight on Avis Budget Gr, Raises Price Target to $85

By Benzinga Newsdesk

Today, 11:01 PM

Morgan Stanley analyst Billy Kovanis maintains Avis Budget Gr (NASDAQ:CAR) with a Equal-Weight and raises the price target from $73 to $85.

CAR

Body and Mind Reports 43% YoY Revenue Growth In Q1, Continued Positive Cash Flow

By Jelena Martinovic

Today, 11:01 PM

Cannabis company Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) announced its financial results Thursday for the first fiscal quarter ended October 31, 2021.

BMMJ

Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform

Related Posts

21 Stocks Moving in Monday’s Pre-Market Session

Analyst Ratings For Take-Two Interactive

Morgan Stanley Maintains Equal-Weight on Avis Budget Gr, Raises Price Target to $85

Body and Mind Reports 43% YoY Revenue Growth In Q1, Continued Positive Cash Flow